|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70 CHF | -4.37% |
|
-6.10% | -5.08% |
| May. 16 | DOCMORRIS : Sell rating from UBS | ZD |
| Apr. 23 | DOCMORRIS : Deutsche Bank remains its Buy rating | ZD |
Zur Rose Group AG reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CHF 1,608.22 million compared to CHF 1,726.5 million a year ago. Net loss was CHF 171.12 million compared to CHF 225.74 million a year ago.
Basic loss per share from continuing operations was CHF 15.88 compared to CHF 23.4 a year ago. Diluted loss per share from continuing operations was CHF 15.88 compared to CHF 23.4 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -5.08% | 963M | |
| -30.37% | 15.68B | |
| -22.51% | 12.39B | |
| -22.88% | 6.74B | |
| -6.01% | 6.29B | |
| +11.76% | 6.26B | |
| +70.00% | 4.95B | |
| -1.90% | 4.7B | |
| -5.58% | 4.03B | |
| -7.87% | 3.62B |
DOCMORRIS AG 
